Partnerships
Kineta has established strategic partnerships to advance the development of our innovative drug programs. We value collaborating with companies and institutions at the forefront of scientific innovation and are interested in building alliances to accelerate the development of next-generation immunotherapies for patients with unmet needs.
To explore partnering opportunities, please contact Kineta
Kineta entered into a strategic research collaboration and license agreement with Merck (known as MSD outside the United States and Canada) focused on accelerating the development of new treatments for neurodegenerative diseases. Under the terms of the agreement, Merck will gain exclusive rights to two novel Kineta pipeline programs for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). Kineta and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck has the right to continue clinical development and commercialization.
Kineta entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). Under this collaboration, Kineta will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KVA12123 (formerly KVA12.1), its novel anti-VISTA monoclonal antibody, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid tumors.